Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.01)
# 2,911
Out of 4,735 analysts
99
Total ratings
37.25%
Success rate
-5.08%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WBA Walgreens Boots Alliance | Maintains: In-Line | $9 → $12 | $11.37 | +5.54% | 13 | Jan 13, 2025 | |
| LH Labcorp Holdings | Upgrades: Outperform | $260 → $265 | $243.99 | +8.61% | 4 | Jan 7, 2025 | |
| XRAY DENTSPLY SIRONA | Downgrades: In-Line | $20 | $18.96 | +5.49% | 7 | Jan 7, 2025 | |
| CAH Cardinal Health | Upgrades: Outperform | $140 | $127.83 | +9.52% | 6 | Jan 7, 2025 | |
| WAY Waystar Holding | Maintains: Outperform | $32 → $36 | $38.09 | -5.49% | 4 | Nov 7, 2024 | |
| MCK McKesson | Maintains: Outperform | $560 → $680 | $586.08 | +16.03% | 4 | Nov 7, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $270 → $250 | $228.00 | +9.65% | 11 | Oct 24, 2024 | |
| TDOC Teladoc Health | Maintains: In-Line | $8 → $9 | $9.50 | -5.26% | 2 | Oct 8, 2024 | |
| IQV IQVIA Holdings | Maintains: Outperform | $270 → $265 | $205.69 | +28.83% | 5 | Oct 8, 2024 | |
| HCAT Health Catalyst | Maintains: Outperform | $8 → $10 | $5.68 | +76.06% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $22 → $20 | $18.70 | +6.95% | 6 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $34 → $45 | $55.52 | -18.95% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $75 | $53.15 | +41.11% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $4 | $3.41 | +17.30% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $20.55 | +11.92% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: In-Line | $165 | $152.65 | +8.09% | 2 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $22.73 | -12.01% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $15.06 | +74.30% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $9.99 | +50.15% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $4.43 | +148.31% | 2 | Jan 4, 2022 |
Walgreens Boots Alliance
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $11.37
Upside: +5.54%
Labcorp Holdings
Jan 7, 2025
Upgrades: Outperform
Price Target: $260 → $265
Current: $243.99
Upside: +8.61%
DENTSPLY SIRONA
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $18.96
Upside: +5.49%
Cardinal Health
Jan 7, 2025
Upgrades: Outperform
Price Target: $140
Current: $127.83
Upside: +9.52%
Waystar Holding
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $38.09
Upside: -5.49%
McKesson
Nov 7, 2024
Maintains: Outperform
Price Target: $560 → $680
Current: $586.08
Upside: +16.03%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $270 → $250
Current: $228.00
Upside: +9.65%
Teladoc Health
Oct 8, 2024
Maintains: In-Line
Price Target: $8 → $9
Current: $9.50
Upside: -5.26%
IQVIA Holdings
Oct 8, 2024
Maintains: Outperform
Price Target: $270 → $265
Current: $205.69
Upside: +28.83%
Health Catalyst
Oct 8, 2024
Maintains: Outperform
Price Target: $8 → $10
Current: $5.68
Upside: +76.06%
Oct 8, 2024
Maintains: In-Line
Price Target: $22 → $20
Current: $18.70
Upside: +6.95%
Oct 8, 2024
Maintains: In-Line
Price Target: $34 → $45
Current: $55.52
Upside: -18.95%
Oct 8, 2024
Maintains: Outperform
Price Target: $62 → $75
Current: $53.15
Upside: +41.11%
Oct 8, 2024
Maintains: In-Line
Price Target: $7 → $4
Current: $3.41
Upside: +17.30%
Sep 23, 2024
Maintains: Outperform
Price Target: $18 → $23
Current: $20.55
Upside: +11.92%
Aug 28, 2024
Reinstates: In-Line
Price Target: $165
Current: $152.65
Upside: +8.09%
Jul 9, 2024
Maintains: Outperform
Price Target: $23 → $20
Current: $22.73
Upside: -12.01%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $15.06
Upside: +74.30%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $9.99
Upside: +50.15%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $4.43
Upside: +148.31%